Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV) by Voysey, M, Pollard, A

“…<strong>Conclusion</strong> This is the first field estimate of the seroefficacy of a Vi-TT vaccine and shows that Typbar TCV substantially reduces the number of serologically defined (sub)clinical infections in infants, children and adults. …”

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India by Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella, Krishna Mohan Vadrevu

“…A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age. …”
Get full text

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children by Krishna Mohan Vadrevu, Raju Dugyala, Niranjana Shamulinga Mahantashetti, Vasant Khalatkar, Krishna Murthy, Sandeep Mogre, Monjori Mitra

Subjects: Get full text

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled,... by Kulkarni, PS, Potey, AV, Bharati, S, Kunhihitlu, A, Narasimha, B, Yallapa, S, Dharmadhikari, A, Gavade, V, Kamat, CD, Mallya, A, Sarma, AD, Goel, S, Pisal, SS, Poonawalla, CS, Venkatesan, R, Jones, E, Flaxman, A, Kim, YC, Pollard, AJ

“…The seroconversion rates on day 29 were 96·7% (95% CI 82·8–99·9) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgG; 93·3% (77·9–99·2) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgA; 100·0% (88·4–100·0) with Sii-PTCV and 3·3% (0·1–17·2) with Typbar-TCV for anti-LPS (paratyphoid); and 93·3% (77·9–99·2) with Sii-PTCV and 0% (0·0–11·6) with Typbar-TCV for SBA titres (paratyphoid). …”

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 co... by Subhash Thuluva, Vikram Paradkar, Ramesh Matur, Kishore Turaga, Subba Reddy GV

“…The TyphiBEVTM group demonstrated noninferiority compared to the Typbar-TCV group at Day 42. The lower 2-sided 95% confidence interval limit of the group difference was −.34%, which met the non-inferiority criteria of ≥10.0%. …”
Get full text

Strategies to Improve Coverage of Typhoid Conjugate Vaccine (TCV) Immunization Campaign in Karachi, Pakistan by Farah Naz Qamar, Rabab Batool, Sonia Qureshi, Miqdad Ali, Tahira Sadaf, Junaid Mehmood, Khalid Iqbal, Akram Sultan, Noah Duff, Mohammad Tahir Yousafzai

“…Here we describe the strategies used to improve acceptance and coverage of Typbar TCV in Lyari Town, Karachi. The mass immunization campaign with Typbar TCV was started as a school- and hospital-based vaccination campaign targeting children between the age of 6 months to 15 years old. …”
Get full text

Prospects of future typhoid and paratyphoid vaccines in endemic countries by Shakya, M, Neuzil, KM, Pollard, AJ

“…There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. …”

Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

“…</p> <p>In this phase III participant-observer-blind randomized controlled trial, children aged 9 months to under-16 years old, were individually randomized (1:1) to either receive the TCV (Typbar-TCV, Bharat Biotech) or a capsular group A meningococcal conjugate vaccine (MenA) as control, and were followed-up for two years.…”

Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines by Fang Gao, Kay Lockyer, Alastair Logan, Sarah Davis, Barbara Bolgiano, Sjoerd Rijpkema, Gopal Singh, Sai D. Prasad, Samuel Pradeep Dondapati, Gurbaksh Singh Sounkhla

“…To facilitate vaccination with the Vi capsular polysaccharide–tetanus toxoid conjugate vaccine, Typbar TCV, and allow it to be transported and stored outside a cold chain just prior to administration, an extended controlled-temperature conditions (ECTC) study was performed to confirm the quality of the vaccine at 40 °C for 3 days at the end of its shelf-life (36 months at 2–8 °C). …”
Get full text

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial by Shakya, M, Voysey, M, Theiss-Nyland, K, Colin-Jones, R, Pant, D, Adhikari, A, Tonks, S, Mujadidi, YF, O'Reilly, P, Mazur, O, Kelly, S, Liu, X, Maharjan, A, Dahal, A, Haque, N, Pradhan, A, Shrestha, S, Joshi, M, Smith, N, Hill, J, Clarke, J, Stockdale, L, Jones, E, Lubinda, T, Bajracharya, B, Dongol, S, Karkey, A, Baker, S, Dougan, G, Pitzer, VE, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ

“…<br><strong> Methods<br></strong> We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). …”

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjug... by Shipra Chaudhary, Gauri Shankar Shah, Nisha Keshary Bhatta, Prakash Poudel, Basant Rai, Surendra Uranw, Prashant Mani Tripathi, Basudha Khanal, Anup Ghimire, Nikita Rai, Birendra Prasad Gupta, Sridhar Vemula, T. Anh Wartel, Sushant Sahastrabuddhe, Tarun Saluja

“…Groups A to C received a single dose (25 μg) of Vi-DT test vaccine from any of the 3 lots, while group D received the comparator, Typbar-TCV®, Vi-tetanus toxoid (Vi-TT) vaccine (25 μg) in 1:1:1:1 ratio and evaluated at 4 weeks postvaccination with 6 months follow-up. …”
Get full text

Implementation of an outbreak response vaccination campaign with typhoid conjugate vaccine – Harare, Zimbabwe, 2019 by M. Poncin, J. Marembo, P. Chitando, N. Sreenivasan, I. Makwara, Z. Machekanyanga, W. Nyabyenda, I. Mukeredzi, M. Munyanyi, A. Hidle, F. Chingwena, C. Chigwena, P. Atuhebwe, H. Matzger, R. Chigerwe, A. Shaum, K. Date, D. Garone, P. Chonzi, J. Barak, I. Phiri, M. Rupfutse, K. Masunda, A. Gasasira, P. Manangazira

“…Method: As part of a larger public health response to a typhoid fever outbreak in Harare, Gavi approved in September 2018 a MOHCC request for 340,000 doses of recently prequalified Typbar-TCV to implement a mass vaccination campaign. …”
Get full text

Immunogenicity and efficacy of conjugated and unconjugated Vi-polysaccharide vaccines in the prevention of typhoid fever by Jin, C

“…</p> <p>The findings from this study represent the first efficacy results and comprehensive assessment of humoral immunity for the only WHO prequalified TCV - Vi-TT (Typbar-TCV, Bharat Biotech). These results contributed to a change in global health policies and funding prioritisation for TCVs. …”

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics by Andrea Haekyung Haselbeck, Birkneh Tilahun Tadesse, Juyeon Park, Malick M. Gibani, Ligia María Cruz Espinoza, Ariane Abreu, Craig Van Rensburg, Michael Owusu-Ansah, Sampson Twuamsi-Ankrah, Michael Owusu, Isaac Aguna, Valentina Picot, Hyonjin Jeon, Ellen Higginson, Sunju Park, Zenaida R. Mojares, Justin Im, Megan E. Carey, Farhana Khanam, Susan Tonks, Gordon Dougan, Deokryun Kim, Jonathan Sugimoto, Vittal Mogasale, Kathleen M. Neuzil, Firdausi Qadri, Yaw Adu-Sarkodie, Ellis Owusu-Dabo, John Clemens, Florian Marks

“…Here, we describe a cluster-randomized trial to investigate population-level protection of TYPBAR-TCV^®, a Vi-polysaccharide conjugated to a tetanus-toxoid protein carrier (Vi-TT) against blood-culture-confirmed typhoid fever, and the synthesis of health economic evidence to inform policy decisions. …”
Get full text